A roundup of recent cases and enforcement actions involving the diagnostics industry
California Pulmonologist Shells Out Over $200K to Settle Kickback Charges Case: The former CEO of a California hospital filed a whistleblower suit accusing the hospital and at least two of its affiliates of hiring a pulmonologist at above fair market compensation to serve as medical director in exchange for patient referrals in violation of the […]
California Pulmonologist Shells Out Over $200K to Settle Kickback Charges
Case: The former CEO of a California hospital filed a whistleblower suit accusing the hospital and at least two of its affiliates of hiring a pulmonologist at above fair market compensation to serve as medical director in exchange for patient referrals in violation of the Anti-Kickback Statute and Stark Law. Rather than risk a trial, the medical director agreed to pay $215,288 to settle the charges, $42,529 of which will go to the whistleblower.
Significance: This is the recent in a long line of cases targeting providers for paying excessive compensation to medical directors in an illegal bid to buy referrals. The hospital defendants named in the original whistleblower lawsuit settled in 2018 at a hefty $8.1 million price tag. The government’s decision to intervene in the case likely exerted enormous pressure on the defendants to settle.
Texas Provider Pays $214K for Violating Federal COVID-19 Workplace Protocols
Case: In what appears to be a first, the Texas parent of an Iowa nursing home has agreed to repay $214,200 in federal monies for not following COVID-19 safety protocols during an outbreak at the facility from April through July 2020. Among other things, the nursing home didn’t properly screen employees or require them to wear personal protective equipment. According to newspaper reports, three employees exhibiting COVID-19 symptoms and who subsequently tested positive for the virus were allowed to come to work and be near vulnerable residents, 11 of whom died during the outbreak.
Significance: The relatively small settlement award belies the importance of this case in that it represents the first settlement with a health care provider for violating the COVID-19 workplace safety protocols during the pandemic. Labs that billed Medicare during the pandemic knowing that they were out of compliance with COVID-19 safety rules run the risk of liability under the False Claims Act. Notably, however, the settlement is based not on FCA liability but on “restitution,” which is typically used to describe repayment of money received by mistake. It’s also worth noting that the company in this case cooperated in the investigation, which is a highly advisable strategy if your lab comes under investigative scrutiny. In the meantime, continue to follow the screening, PPE and other safety rules scrupulously.
Texas Says Employee Can Sue Testing Lab for Botching Random Drug Test Required by Employer
Case: A pipefitter who got fired after flunking a random drug test sued the testing lab and provider that collected the hair follicle sample for negligence. The defendants claimed that they owed a duty of care to the welding company who employed him but not to the pipefitter himself. The trial court agreed and tossed the claim without a trial. But the state appeals court reversed, finding that the pipefitter did have a valid negligence claim.
Significance: This is the first case in which a Texas court has been asked to decide whether labs and other third parties owe a duty of reasonable care in collection and analysis of drug tests performed on an employee at the requirement of his employer. The court in this case answered the question, citing Texas Supreme Court language acknowledging that “there is a serious risk that an employee can be harmed by a false positive drug test” and the fact that there’s no statute or regulation protecting employees who are subject to random drug tests [Mendez v. Houston Harris Area Safety Council, Inc., 2021 Tex. App. LEXIS 3243, 2021 WL 1679544].
University of Miami Settles Lab Testing False Claim Charges for $22 Million
Case: In this particular case, “The U” stands for unnecessary, as in medically unnecessary lab tests billed to Medicare by the University of Miami’s lab and off campus hospital-based facilities. The $22 million that the UM has agreed to fork over settles a trio of whistleblower lawsuits filed in 2013 and 2014, alleging that UM and its affiliates:
- Converted multiple physician offices to Off-Campus Hospital Facilities so it could bill Medicare for higher rates and without providing beneficiaries the required notice;
- Used its electronic ordering system to automatically prompt physicians to order multiple medically unnecessary tests for kidney transplant patients
- Submitted inflated claims for reimbursement for pre-transplant lab testing done by an affiliate that the affiliate should have billed for directly and then using the Medicare payments to pay the affiliate kickbacks for referring surgical patients.
Significance: The first takeaway of the settlement is to emphasize the importance of ensuring compliance with the Off-Campus billing of Medicare patients notice requirements. Such requirements count as conditions of payment and not complying with them can turn the claim into a false claim. The other moral of the UM story is that “standing” orders remain highly risky and are allowed only when strictly tailored to each patient’s individual circumstances and needs.
Florida Telemarketers Indicted for $47 Million Genetic Test Fraud Scheme
Case: A federal grand jury indicted three telemarketing company owners for a smorgasbord of fraud, kickback and money laundering violations that allegedly cost Medicare $47 million medically unnecessary genetic tests. Following what has become a familiar pattern, the schemers ran a telemarketing campaign designed to get Medicare beneficiaries to undergo genetic cancer screening, regardless of their medical need. They then recruited a network of physicians who were willing to order the tests without seeing the patients in exchange for kickbacks. Those orders were then sold to the labs that performed the tests and sent the bill to Medicare.
Significance: Telemarketing schemes were just starting to penetrate the radar of federal enforcers before the pandemic hit. As utilization of telemedicine has increased, so has the level of enforcement scrutiny and activity, the culmination of which was last year’s Operation Rubberstamp, a massive federal takedown. While not specifically its focus, genetic testing labs often play a key role in telemarketing fraud cases, as in this most recent indictment.
This content is exclusive to Lab Compliance Advisor subscribers
Start a Free Trial for immediate access to this article and our entire archive of over 20 years of LCA reports.